Workflow
氨氯地平贝那普利胶囊
icon
Search documents
北京福元医药股份有限公司 关于氨氯地平贝那普利胶囊获得药品注册证书的公告
Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Amlodipine Benazepril Capsules, which will enhance the company's product line and market competitiveness [1][4]. Drug Registration Certificate Details - The drug is approved for production by the National Medical Products Administration, with the registration certificate number 2025S02582 [1]. - Amlodipine Benazepril Capsules are indicated for patients whose blood pressure is not adequately controlled by either Amlodipine or Benazepril alone, or for those requiring a switch from separate Amlodipine and Benazepril tablets [1]. R&D Investment - The company has invested a total of RMB 8.1616 million (approximately 1.1 million USD) in the research and development of this drug [2]. Market Situation of Similar Drugs - According to data from Minai Network, the sales revenue of Amlodipine Benazepril oral formulations in China is approximately RMB 1.12 billion (about 160 million USD) for 2024 [3]. - The sales distribution includes RMB 727 million (about 102 million USD) from urban public hospitals and county-level public hospitals, RMB 167 million (about 24 million USD) from urban community centers and township health clinics, and RMB 226 million (about 32 million USD) from urban pharmacies and online pharmacies [3]. Impact on the Company - The approval of the drug will enrich the company's product line and enhance its market competitiveness [4].
早新闻 | 美联储,重大变数
Zheng Quan Shi Bao· 2025-09-04 23:48
Macro Highlights - The State Council issued an opinion to release the potential of sports consumption and promote high-quality development of the sports industry, proposing 6 key measures with 20 specific actions [1] - The measures include expanding the supply of sports products, stimulating consumer demand, strengthening sports enterprises, fostering growth points in the sports industry, enhancing support for industry elements, and improving service levels [1] - The National Standardization Administration plans to revise and formulate over 4,000 national standards focusing on key areas such as artificial intelligence and the Internet of Things to support the transformation and upgrading of the manufacturing industry [1] Company News - Jiahe Meikang announced that Hongyun Jiukang plans to reduce its stake in the company by no more than 1% [4] - Bolong Technology's supervisory board chairman intends to reduce his stake by no more than 0.75% [4] - Lianhuan Pharmaceutical received a drug registration certificate for Amlodipine Besylate Tablets [4] - Tianyu Co., Ltd. obtained a drug registration certificate for Candesartan Cilexetil Tablets [4] - Kebo Da plans to acquire 60% of Kebo Da Intelligent Technology for 345 million yuan [4] - Youyan Powder Materials reported that its newly developed heat dissipation copper powder cannot be used as a 3D printing material [4] - Southeast Network Frame won the bid for the joint development project of Wuyuan Street [4] - Lepu Medical completed the first dosing of the Phase II clinical trial for MWN105 injection [4] - Zhonghaidah clarified that its designated robot company is not UBTECH [4] - Information Development aims to expand cooperation opportunities with the Robotaxi industry chain [4] Additional Company News - Jingong Steel Structure's subsidiary won a land bid in Shanghai for 546 million yuan [5] - Fuyuan Pharmaceutical received a drug registration certificate for Amlodipine Benazepril Capsules [5] - Ningbo Construction's subsidiary won construction projects totaling 1.117 billion yuan [5]
福元医药:关于氨氯地平贝那普利胶囊获得药品注册证书的公告
Core Viewpoint - Fuyuan Pharmaceutical has received approval from the National Medical Products Administration for the production of Amlodipine Benazepril Capsules, marking a significant milestone for the company in expanding its product offerings [1] Group 1 - The approved drug contains Amlodipine (5mg) and Benazepril (10mg) per capsule, indicating a combination therapy for hypertension [1] - The drug registration certificate number is 2025S02582, which formalizes the approval process [1]
福元医药: 北京福元医药股份有限公司关于氨氯地平贝那普利胶囊获得药品注册证书的公告
Zheng Quan Zhi Xing· 2025-09-04 08:16
Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Amlodipine Besilate and Benazepril Hydrochloride Capsules, which will enhance the company's product line and market competitiveness [1][2]. Drug Registration Certificate Details - The drug is classified as a Class 3 chemical drug and is prescribed for patients whose blood pressure is not adequately controlled by Amlodipine or Benazepril alone [1]. - The drug's specifications include 5mg of Amlodipine Besilate and 10mg of Benazepril Hydrochloride per capsule [1]. - The registration certificate number is 2025S02582, and the drug is categorized as a prescription medication [1]. Market Information - The total sales of Amlodipine Besilate and Benazepril Hydrochloride Capsules in China for 2024 are estimated to be approximately 1.12 billion yuan, with sales in urban public hospitals and county-level public hospitals accounting for 727 million yuan [1]. - Sales from urban community centers and township health clinics are projected to be 167 million yuan, while urban pharmacies and online pharmacies are expected to generate 226 million yuan [1]. Company Impact - The approval of the drug registration certificate is expected to enrich the company's product portfolio and improve its market competitiveness [2].
福元医药:氨氯地平贝那普利胶囊获得药品注册证书
Zhi Tong Cai Jing· 2025-09-04 07:42
Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received the drug registration certificate from the National Medical Products Administration for Amlodipine Benazepril Capsules, indicating a significant milestone for the company in the hypertension treatment market [1]. Group 1: Product Approval - The National Medical Products Administration has issued a drug registration certificate for Amlodipine Benazepril Capsules, which contain 5mg of Amlodipine and 10mg of Benazepril per capsule [1]. - This product is intended for patients whose blood pressure is not adequately controlled by either Amlodipine or Benazepril alone, or for those who are switching from separate Amlodipine and Benazepril tablets [1]. Group 2: Market Context - Amlodipine Benazepril was originally developed by Novartis and was first approved in the United States in March 1995 [1]. - The original manufacturer’s version of Amlodipine Benazepril has not yet been launched in China, presenting a potential market opportunity for Fuyuan Pharmaceutical [1].
福元医药:氨氯地平贝那普利胶囊获药品注册证书
Xin Lang Cai Jing· 2025-09-04 07:42
福元医药公告,近日收到国家药监局颁发的氨氯地平贝那普利胶囊(规格:每粒含苯磺酸氨氯地平5mg (按C H ClN O 计)与盐酸贝那普利10mg)药品注册证书,批准该药品生产。该药品用于治疗高血 压,由诺华研发,最早于1995年3月在美国获批上市,本品适用于单独服用氨氯地平或贝那普利不能满 意控制血压的患者,或同时服用氨氯地平片和贝那普利片的替代治疗。公司于2024年3月21日获得申报 受理通知书,并于近日获得国家药监局批准。根据国家相关政策规定,本次获得《药品注册证书》,视 同通过一致性评价。 ...
福元医药(601089.SH):氨氯地平贝那普利胶囊获得药品注册证书
智通财经网· 2025-09-04 07:41
氨氯地平贝那普利胶囊由诺华研发,最早于1995年3月在美国获批上市,原研厂家的氨氯地平贝那普利 胶囊尚未在中国上市。本品用于治疗高血压,但非初治高血压。本品适用于单独服用氨氯地平或贝那普 利不能满意控制血压的患者;或同时服用氨氯地平片和贝那普利片的替代治疗。 智通财经APP讯,福元医药(601089.SH)发布公告,近日,公司收到了国家药品监督管理局(简称"国家药 监局")颁发的氨氯地平贝那普利胶囊(规格:每粒含苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计)与盐酸贝那 普利10mg)《药品注册证书》(证书编号:2025S02582),批准该药品生产。 ...
华润双鹤:全资子公司部分药品取得注册证
Mei Ri Jing Ji Xin Wen· 2025-08-28 01:33
Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiaries have received drug registration certificates for several medications from the National Medical Products Administration [1] Group 1: Company Developments - Beijing Wanhui Double Crane Pharmaceutical Co., Ltd., China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd., and Double Crane Pharmaceutical (Hainan) Co., Ltd. have each received drug registration certificates for Amlodipine Benazepril Capsules, Tocilizumab Sustained-Release Tablets, and Valsartan Fumarate Tablets respectively [1]
中国医药上半年净利润2.94亿元;治疗不孕不育长效注射液获批
Policy Developments - The State Council aims to develop the China (Jiangsu) Pilot Free Trade Zone into a globally influential biopharmaceutical industry hub, with a plan that includes 18 key tasks for integrated innovation across the entire industry chain by 2030 [1] Drug Approvals - China Resources Double Crane announced that its subsidiaries received drug registration certificates for three products, which will enhance the company's product line and market competitiveness [2] - Tianyao Pharmaceutical's subsidiary received a drug registration certificate for a new eye drop product, which is expected to positively impact the company's domestic market expansion and performance [3] Financial Reports - China National Pharmaceutical Group reported a revenue of 17.076 billion yuan for the first half of 2025, a decrease of 6.71% year-on-year, with a net profit of 294 million yuan, down 16.19% [4] - Jiahe Meikang reported a revenue of 219 million yuan for the first half of 2025, a decline of 27.22%, resulting in a net loss of 116 million yuan [5] - Renfu Pharmaceutical reported a revenue of 12.064 billion yuan, a decrease of 6.20%, but a net profit increase of 3.92% to 1.155 billion yuan [6] Investment Activities - Tibet Pharmaceutical plans to invest 60 million USD in Accuredit Therapeutics Limited, acquiring a 40.82% stake, focusing on gene editing technologies [7] Industry Developments - The first long-acting injection for infertility treatment has been approved, providing a more efficient and convenient option for patients compared to traditional daily injections [8] - A study revealed a protein linked to infertility and cancer, suggesting potential new treatment avenues for both conditions [9] Shareholder Actions - Dabo Medical announced a plan for a shareholder to reduce their stake by up to 2% of the company's shares [10] - Kangchen Pharmaceutical's executive plans to sell up to 87,500 shares due to personal financial needs [11]
华润双鹤:关于全资子公司部分药品获得药品注册证书的公告
Core Viewpoint - China Resources Double Crane announced the receipt of drug registration certificates for three products from the National Medical Products Administration, indicating a significant step in expanding its pharmaceutical portfolio [1] Group 1: Company Developments - The wholly-owned subsidiaries of China Resources Double Crane, including Beijing Wanhui Double Crane Pharmaceutical Co., Ltd., China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd., and Double Crane Pharmaceutical (Hainan) Co., Ltd., received registration certificates for Amlodipine Benazepril Capsules, Tocilizumab Sustained-Release Tablets, and Vornorex Fumarate Tablets [1]